Announced
Synopsis
GTCR-backed TerSera Therapeutics, a drug manufacturer, agreed to acquire Xermelo business from Lexicon Pharmaceuticals, a pharmaceutical company, for $159m. "Xermelo is a great addition to the TerSera portfolio, which now includes six commercial products in two attractive therapeutic areas. This acquisition further demonstrates our commitment to the Leaders Strategy™, having partnered with Ed three times and built three unique, growing specialty pharmaceutical companies," Dean Mihas, GTCR Managing Director.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.